Evidence map›Paper›PMID 40206277›Full record

ReviewJournal of clinical and translational hepatology2025

Hepatocellular Carcinoma and the Role of Liver Transplantation: An Update and Review.

Lynette M Sequeira, N Begum Ozturk, Leandro Sierra, Merve Gurakar, Merih Deniz Toruner, Melanie Zheng, Cem Simsek, Ahmet Gurakar, Amy K Kim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical and translational hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lynette M SequeiraDepartment of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
N Begum OzturkDepartment of Internal Medicine, Beaumont Hospital, Royal Oak, MI, USA.
Leandro SierraDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Merve GurakarDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Merih Deniz TorunerWarren Alpert Medical School of Brown University, Providence, RI, USA.
Melanie ZhengDepartment of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Cem SimsekDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ahmet GurakarDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-2221-9148
Amy K KimDivision of Gastroenterology and Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death worldwide. Multiple treatment modalities are available for the management of HCC, depending on its stage as determined by the Barcelona Clinic Liver Cancer staging system. Because liver transplantation (LT) theoretically removes the cancer and replaces the organ at risk for future malignancy, LT is often considered the most definitive and one of the most efficacious treatment options for HCC. Nevertheless, the success and efficacy of liver transplantation depend on various tumor characteristics. As a result, multiple criteria have been developed to assess the appropriateness of a case of HCC for LT, with the pioneering Milan Criteria established in 1996. Over the past 20 to 30 years, these criteria have been critically evaluated, expanded, and often liberalized to make LT for patients with HCC a more universally applicable option. Furthermore, the development of other treatment modalities has enabled downstaging and bridging strategies for HCC prior to LT. In this narrative and comprehensive review, we provided an update on recent trends in the epidemiology of HCC, selection criteria for LT, implementation of LT across different regions, treatment modalities available as bridges, downstaging strategies, alternatives to LT, and, finally, post-LT surveillance.

Indexed as

Alpha-fetoproteinsDeceased donor liver transplantHepatocellular carcinoma diagnosisHepatocellular carcinoma therapyImmunotherapyLiver neoplasmsLiver transplantationLiving donor liver transplantMilan CriteriaModel for end-stage liver disease scoreMolecular targeted therapyRadiofrequency ablationSorafenibTransarterial chemoembolization (TACE)Waiting lists

Identifiers

PMID40206277
PMCPMC11976436

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.